Form 8-K - Current report:
SEC Accession No. 0000950170-25-104164
Filing Date
2025-08-06
Accepted
2025-08-06 16:41:24
Documents
12
Period of Report
2025-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tnya-20250806.htm   iXBRL 8-K 49934
2 EX-99.1 tnya-ex99_1.htm EX-99.1 169674
3 GRAPHIC img92481827_0.jpg GRAPHIC 6181
  Complete submission text file 0000950170-25-104164.txt   351122

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20250806.xsd EX-101.SCH 25873
14 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20250806_htm.xml XML 4909
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 251190294
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)